Four Colorado Companies Participate at the 2007 Rocky Mountain Bioscience Venture Capital Meeting on the Mountain in Park City, Utah
Summary
The company was formed in 2006 to capitalize on the intellectual property of its Founding Scientists and University of Colorado Cancer Center members, Richard C. Duke, Ph.D., Donald Bellgrau, Ph.D., Paul A. Bunn, M.D., Daniel Chan, Ph.D., Lajos Gera, Ph.D., Jaime Modiano, D.V.M., Ph.D. and John Stewart, Ph.D.* Apoplogic – http://www.apoplogic.comApopLogic Pharmaceuticals, LLC is a startup phase biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products that target apoptotic cell death pathways found in cancers, leukemias and lymphomas.The company was formed in 2006 to capitalize on the intellectual property of its Founding Scientists and University of Colorado Cancer Center members, Richard C. Duke, Ph.D., Donald Bellgrau, Ph.D., Paul A. Bunn, M.D., Daniel Chan, Ph.D., Lajos Gera, Ph.D., Jaime Modiano, D.V.M., Ph.D. and John Stewart, Ph.D.* Microphage – http://www.microphage.comMicroPhage was founded and incorporated as a Delaware corporation in June 2002 by Jack Wheeler and Kent Voorhees Ph.D., to commercialize a bacterial detection technology licensed from the Colorado School of Mines.Originally based upon the detection of the bacteriophage specific capsid protein with MALDI-TOF Mass Spectrometry, the company quickly demonstrated the reliability and ease of use of detecting bacteriophage with alternative methods including; lateral flow immunochromatography (LFI), enzyme linked Immunosorbant assay (ELISA), optical immunoassays (OIA) and polymerase chain reaction (PCR).“Dorsey & Whitney’s efforts to bring investors to the Rocky Mountain region to become more familiar with some of our most promising start-ups is greatly appreciated.